Tigris Pharmaceuticals

Tigris enrolls first patient in breast cancer study

Friday, May 27, 2011

Tigris Pharmaceuticals has enrolled its first patient in a randomized phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients. Molecular profiling will be used to pre-screen patients for a biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown to predict sensitivity to AFP-464.

[Read More]